Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Matos

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|July 21, 2020
Atypical patterns of response and progression in the era of immunotherapy combinationsRoberto Ferrara, Ignacio Matos
Expert Opinion on Emerging Drugs|September 1, 2016
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancerIgnacio Matos, Elena Elez, Jaume Capdevila, et al.
Targeted Oncology|November 17, 2017
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine TumorsFabiola Amair-Pinedo, Ignacio Matos, Tamara Saurí, et al.
Journal of Gastrointestinal Cancer|April 12, 2017
The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the BedJorge Hernando-Cubero, Ignacio Matos-García, Vicente Alonso-Orduña, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2023
Druggable Targets in Cytokine Release SyndromesCarlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, et al.
Expert Opinion on Investigational Drugs|March 26, 2019
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trialsIgnacio Matos, Alba Noguerido, Javier Ros, et al.
Expert Opinion on Drug Safety|August 4, 2018
The safety of ramucirumab for the treatment of colorectal cancerAlba Noguerido, Núria Mulet-Margalef, Ignacio Matos, et al.
The Oncologist|March 11, 2023
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical TrialsLee X Li, Federico Cappuzzo, Ignacio Matos, et al.
Trends in Cancer|February 27, 2020
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?Jacob J Adashek, Ishwaria M Subbiah, Ignacio Matos, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|July 21, 2020
Atypical patterns of response and progression in the era of immunotherapy combinationsRoberto Ferrara, Ignacio Matos
Expert Opinion on Emerging Drugs|September 1, 2016
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancerIgnacio Matos, Elena Elez, Jaume Capdevila, et al.
Targeted Oncology|November 17, 2017
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine TumorsFabiola Amair-Pinedo, Ignacio Matos, Tamara Saurí, et al.
Journal of Gastrointestinal Cancer|April 12, 2017
The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the BedJorge Hernando-Cubero, Ignacio Matos-García, Vicente Alonso-Orduña, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2023
Druggable Targets in Cytokine Release SyndromesCarlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, et al.
Expert Opinion on Investigational Drugs|March 26, 2019
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trialsIgnacio Matos, Alba Noguerido, Javier Ros, et al.
Expert Opinion on Drug Safety|August 4, 2018
The safety of ramucirumab for the treatment of colorectal cancerAlba Noguerido, Núria Mulet-Margalef, Ignacio Matos, et al.
The Oncologist|March 11, 2023
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical TrialsLee X Li, Federico Cappuzzo, Ignacio Matos, et al.
Trends in Cancer|February 27, 2020
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?Jacob J Adashek, Ishwaria M Subbiah, Ignacio Matos, et al.
Pageof 4